Investorideas.com newswire, breaking biotechnology and pharma news

Monday, June 6, 2011

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Introduces "RX Air Plus," One of the World's Most Advanced Air Purification Systems

CENTERVILLE, MA � June 6, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce it has commenced marketing the "RX Air Plus" Air Purification System, which the Company believes could revolutionize the air purification marketplace.
The new system may prove to be the most effective air purification system in the world today, as the "RX Air Plus" System packages the RX-3000, built by the Company's RxAir subsidiary, along with 2 ViraTech UV-400 units. The Company believes this to be the only air purification system in the world utilizing two different FDA cleared Class II Medical devices as an integrated system. RX Air Plus brings together the two technologies, which combine to kill over 99% of bacteria and other contaminants, while reducing all odors and volatile organic compounds, as well as capturing over 99.97 % of all particulates within indoor areas up to 1500 square feet in size.
"No other Company offers a system which matches the capabilities of these combined technologies," said John Lennon, President of UV Flu Technologies. "The 'RX Air Plus' offers two of the most unique and effective products in the air purification marketplace today. The two ViraTech UV-400 units utilize hi-intensity germicidal UV lamps contained within a patented cartridge, which kills organic contaminants while also breaking down odors and concentrations of VOCs. The RX-3000 is one of the finest HEPA based air purifiers, capturing over 99.97% of particulates. The quality of indoor air protected by this system is typically purer than outdoor air while never having to open a window. The Company is offering the system to new customers and distributors immediately. We also plan to approach the over 1000 customer locations already utilizing the RX-3000 as possible upgrade opportunities."
"We also believe this system is going to have numerous applications in the Mideast, where microscopic sand particles are a major issue with respect to poor indoor air quality. To this end, the Company is in talks with several companies with respect to distribution in the Mideast, and expects to have an agreement in place this quarter," said Mr. Lennon.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/

Request info:
http://www.investorideas.com/Resources/Newsletter.asp

No comments:

Post a Comment